Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J0736
300 MG
Medicare payment limit per unit (Q4 2026): $1.854
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 9 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 9 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$1.854per 300 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $1.854 | 300 MG | 20% | −6.1% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $1.974 | 300 MG | 20% | +6.4% | — |
| Q2 2026 |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 00338-3410-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 1 | 24 | $44.50 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin phosphate |
| 00338-3612-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 2 | 48 | $88.99 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin phosphate |
| 00338-3616-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 2 | 48 | $88.99 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin phosphate |
| 00338-3814-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 3 | 72 | $133.49 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin phosphate |
| 00338-4114-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 3 | 72 | $133.49 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin phosphate |
| 43066-0993-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 2 | 48 | $88.99 | ASP | Q1 2024 – Q4 2026 | ListedClindamycin phosphate |
| 43066-0995-24 | Clindamycin PhosphateBaxter Healthcare Corporation | 50 × 24 | 3 | 72 | $133.49 | ASP | Q1 2024 – Q4 2026 | ListedClindamycin phosphate |
| 72572-0074-24 | Clindamycin PhosphateCivica, Inc. | 50 × 24 | 2 | 48 | $88.99 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
| 72572-0076-24 | Clindamycin PhosphateCivica, Inc. | 50 × 24 | 3 | 72 | $133.49 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
| 00404-9837-02 | CleocinHenry Schein Inc. | 2 × 1 | 1 | 1 | $1.85 | ASP | Q1 2024 – Q4 2026 | ListedCleocin Phosphate |
| 00404-9838-04 | Clindamycin PhosphateHenry Schein Inc. | 4 × 1 | 2 | 2 | $3.71 | ASP | Q4 2025 – Q4 2026 | ListedClindamycin |
| 00143-9267-01 | Clindamycin PhosphateHikma Pharmaceuticals USA Inc. | 50 × 1 | 1 | 1 | $1.85 | ASP | Q4 2024 – Q4 2026 | ListedClindamycin in 5 percent Dextrose |
| 00143-9268-01 | Clindamycin PhosphateHikma Pharmaceuticals USA Inc. | 50 × 1 | 2 | 2 | $3.71 | ASP | Q4 2024 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
| 00143-9269-01 | Clindamycin PhosphateHikma Pharmaceuticals USA Inc. | 50 × 1 | 3 | 3 | $5.56 | ASP | Q4 2024 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
| 00009-0728-09 | CleocinPfizer Inc | 60 × 5 | 30 | 150 | $278.10 | ASP | Q3 2023 – Q4 2026 | Excluded listingCleocin Phosphate |
| 00009-0775-26 | CleocinPfizer Inc | 4 × 25 | 2 | 50 | $92.70 | ASP | Q3 2023 – Q4 2026 | ListedCleocin Phosphate |
| 00009-0870-26 | CleocinPfizer Inc | 2 × 25 | 1 | 25 | $46.35 | ASP | Q3 2023 – Q4 2026 | ListedCleocin Phosphate |
| 00009-0902-18 | CleocinPfizer Inc | 6 × 25 | 3 | 75 | $139.05 | ASP | Q3 2023 – Q4 2026 | ListedCleocin Phosphate |
| 00009-3051-02 | CleocinPfizer Inc | 2 × 25 | 1 | 25 | $46.35 | ASP | Q3 2023 – Q4 2026 | Excluded listingCleocin Phosphate |
| 00009-4073-04 | CleocinPfizer Inc | 4 × 25 | 2 | 50 | $92.70 | ASP | Q3 2023 – Q4 2026 | ListedCleocin Phosphate |
| 00009-5095-06 | CleocinPfizer Inc | 6 × 25 | 3 | 75 | $139.05 | ASP | Q3 2023 – Q4 2026 | Excluded listingCleocin Phosphate |
| 25021-0115-02 | Clindamycin PhosphateSagent Pharmaceuticals | 2 × 25 | 1 | 25 | $46.35 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin |
| 25021-0115-04 | Clindamycin PhosphateSagent Pharmaceuticals | 4 × 25 | 2 | 50 | $92.70 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin |
| 25021-0115-06 | Clindamycin PhosphateSagent Pharmaceuticals | 6 × 25 | 3 | 75 | $139.05 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin |
| 00781-3288-09 | Clindamycin PhosphateSandoz Inc. | 50 × 24 | 1 | 24 | $44.50 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
| 00781-3289-09 | Clindamycin PhosphateSandoz Inc. | 50 × 24 | 2 | 48 | $88.99 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
| 00781-3290-09 | Clindamycin PhosphateSandoz Inc. | 50 × 24 | 3 | 72 | $133.49 | ASP | Q3 2023 – Q4 2026 | ListedClindamycin in 5 Percent Dextrose |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 72611-0634-25 | Clindamycin PhosphateALMAJECT | 2 × 25 | 1 | 25 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2024 | Dates changed | P — Payment change | Added Jul 1, 2023 · action effective Jan 1, 2024 · termination — |
| Q3 2023 | Added to HCPCS | A — Added | Added date Jul 1, 2023 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Apr 1, 2026 – Jun 30, 2026 |
| $1.855 |
| 300 MG |
| 20% |
| −3.0% |
| — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.913 | 300 MG | 20% | +4.6% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.828 | 300 MG | 20% | +9.4% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.671 | 300 MG | 20% | +3.6% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.613 | 300 MG | 20% | −24.4% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $2.134 | 300 MG | 20% | −13.4% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $2.465 | 300 MG | 20% | +3.1% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $2.391 | 300 MG | 20% | +5.5% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $2.266 | 300 MG | 20% | +19.0% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $1.904 | 300 MG | 20% | −5.5% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $2.015 | 300 MG | 20% | +25.5% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $1.606 | 300 MG | 20% | — | Added July 2023 |
|---|
| 72611-0639-25 | Clindamycin PhosphateALMAJECT | 4 × 25 | 2 | 50 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingClindamycin phosphate |
|---|
| 72611-0642-25 | Clindamycin PhosphateALMAJECT | 6 × 25 | 3 | 75 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingClindamycin phosphate |
|---|
| 72611-0645-55 | Clindamycin PhosphateALVOGEN | 60 × 5 | 30 | 150 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingClindamycin phosphate |
|---|
| 67457-0814-02 | Clindamycin PhosphateMYLAN INSTITUTIONAL LLC | 2 × 25 | 1 | 25 | ASP | Q3 2023 – Q4 2023Not in Q4 2026 file | Excluded listingClindamycin |
|---|
| 67457-0815-04 | Clindamycin PhosphateMYLAN INSTITUTIONAL LLC | 4 × 25 | 2 | 50 | ASP | Q3 2023 – Q4 2023Not in Q4 2026 file | Excluded listingClindamycin |
|---|
| 67457-0816-06 | Clindamycin PhosphateMYLAN INSTITUTIONAL LLC | 6 × 25 | 3 | 75 | ASP | Q3 2023 – Q4 2023Not in Q4 2026 file | Excluded listingClindamycin |
|---|
| 00009-0302-25 | CleocinPFIZER INC. | 2 × 25 | 1 | 25 | ASP | Q3 2023 – Q4 2023Not in Q4 2026 file | Excluded listingCleocin Phosphate |
|---|
| 00009-0602-25 | CleocinPFIZER INC. | 4 × 25 | 2 | 50 | ASP | Q3 2023 – Q4 2023Not in Q4 2026 file | Excluded listingCleocin Phosphate |
|---|
| 00009-0901-25 | CleocinPFIZER INC. | 6 × 25 | 3 | 75 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingCleocin Phosphate |
|---|
| 25021-0115-51 | Clindamycin PhosphateSagent Pharmaceuticals | 60 × 1 | 30 | 30 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | Excluded listingClindamycin |
|---|
| 00781-9220-09 | Clindamycin PhosphateSANDOZ | 50 × 24 | 1 | 24 | ASP | Q3 2023Not in Q4 2026 file | Excluded listingClindamycin in 5 Percent Dextrose |
|---|
| 00781-9221-09 | Clindamycin PhosphateSANDOZ | 50 × 24 | 2 | 48 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingClindamycin in 5 Percent Dextrose |
|---|
| 00781-9222-09 | Clindamycin PhosphateSANDOZ | 50 × 24 | 3 | 72 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingClindamycin in 5 Percent Dextrose |
|---|